Freeline Therapeutics Holdings plc announced that Chief Medical Officer (“CMO”) Julie Krop, MD will be leaving the Company to pursue other opportunities. Alison Long, MD, PhD, SVP, Head of Clinical Development, who has been instrumental in catalyzing the momentum in the Company’s clinical and pre-clinical programs, will assume the role of interim CMO while an external search for a new CMO is conducted. Dr. Long is an established leader with 30 years of combined clinical and industry experience, including extensive gene therapy drug development experience previously leading clinical departments and programs at uniQure N.V. and, most recently, Spark Therapeutics Inc., where she was Head of Clinical Research & Development.